SOCS1 Deficiency Promotes Hepatocellular Carcinoma via SOCS3-Dependent CDKN1A Induction and NRF2 Activation
Authors:
- Gulam Musawwir KhanGulam Musawwir Khan
- Nadia BoufaiedNBNadia Boufaied
- Mehdi YeganehMYMehdi Yeganeh
- Rajani KandhiRKRajani Kandhi
- Stephanie PetkiewiczSPStephanie Petkiewicz
- Ankur SharmaASAnkur Sharma
- Akihiko YoshimuraAYAkihiko Yoshimura
- Gerardo FerbeyreGerardo Ferbeyre
- David P. LabbéDLDavid P. Labbé
- Sheela RamanathanSRSheela Ramanathan
- Subburaj IlangumaranSISubburaj Ilangumaran
Open Access
Abstract
SOCS1 deficiency, which increases susceptibility to hepatocellular carcinoma (HCC), promotes CDKN1A expression in the liver. High CDKN1A expression correlates with disease severity in many cancers. Here, we demonstrate a crucial pathogenic role of CDKN1A in diethyl nitrosamine (DEN)-induced HCC in SOCS1-deficient mice. Mechanistic studies on DEN-induced genotoxic response revealed that SOCS1-deficient hepatocytes upregulate SOCS3 expression, SOCS3 promotes p53 activation, and Cdkn1a induction that were abolished by deleting either Socs3 or Tp53. Previous reports implicate CDKN1A in promoting oxidative stress response mediated by NRF2, which is required for DEN-induced hepatocarcinogenesis. We show increased induction of NRF2 and its target genes in SOCS1-deficient livers following DEN treatment that was abrogated by the deletion of either Cdkn1a or Socs3. Loss of SOCS3 in SOCS1-deficient mice reduced the growth of DEN-induced HCC without affecting tumor incidence. In the TCGA-LIHC dataset, the SOCS1-low/SOCS3-high subgroup displayed increased CDKN1A expression, enrichment of NRF2 transcriptional signature, faster disease progression, and poor prognosis. Overall, our findings show that SOCS1 deficiency in hepatocytes promotes compensatory SOCS3 expression, p53 activation, CDKN1A induction, and NRF2 activation, which can facilitate cellular adaptation to oxidative stress and promote neoplastic growth. Thus, the NRF2 pathway represents a potential therapeutic target in SOCS1-low/SOCS3-high HCC cases.Keywords
Funding Information
- Canadian Institutes of Health Research (PJT-153174, PJT-162246, JSPS KAKENHI 19K07514, 21H05044, AMED-CREST 21gm1110009, AMED-Moonshot 21zf0127003h0001, PJT-153174, PJT-162246)
- graduate scholarships from the FRQNT (PJT-153174, PJT-162246, JSPS KAKENHI 19K07514, 21H05044, AMED-CREST 21gm1110009, AMED-Moonshot 21zf0127003h0001, PJT-153174, PJT-162246)
- Canadian Institutes of Health Research (PJT-153174, PJT-162246, JSPS KAKENHI 19K07514, 21H05044, AMED-CREST 21gm1110009, AMED-Moonshot 21zf0127003h0001, PJT-153174, PJT-162246)
This publication has 58 references indexed in Scilit:
- Human hepatocyte carcinogenesisInternational Journal of Oncology, 2013
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesisNature, 2011
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancerJournal of Clinical Investigation, 2010
- Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant ResponseMolecular Cell, 2009
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- Hepatocyte Necrosis Induced by Oxidative Stress and IL-1α Release Mediate Carcinogen-Induced Compensatory Proliferation and Liver TumorigenesisCancer Cell, 2008
- Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3Journal of Experimental Medicine, 2007